2018
Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium
Harris HR, Babic A, Webb PM, Nagle CM, Jordan SJ, Group O, Risch H, Rossing M, Doherty J, Goodman M, Modugno F, Ness R, Moysich K, Kjær S, Høgdall E, Jensen A, Schildkraut J, Berchuck A, Cramer D, Bandera E, Wentzensen N, Kotsopoulos J, Narod S, Phelan C, McLaughlin J, Anton-Culver H, Ziogas A, Pearce C, Wu A, Terry K, Consortium O. Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2018, 27: 174-182. PMID: 29141849, PMCID: PMC5877463, DOI: 10.1158/1055-9965.epi-17-0655.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerPolycystic ovary syndromeOvarian cancer riskMenstrual cycle lengthOvarian cancerCancer riskDecreased riskSelf-reported polycystic ovary syndromeLogistic regressionCycle lengthStudy-specific ORsIrregular menstrual cyclesSerous borderline tumorsRisk factor associationsCase-control studyOvarian cancer histotypesPolytomous logistic regressionMucinous tumorsOvary syndromeBorderline tumorsHistologic subtypeOvarian diseaseMenstrual cycleCancer histotypesHistotype
2017
Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium
Babic A, Harris HR, Vitonis AF, Titus LJ, Jordan SJ, Webb PM, Group A, Risch H, Rossing M, Doherty J, Wicklund K, Goodman M, Modugno F, Moysich K, Ness R, Kjaer S, Schildkraut J, Berchuck A, Pearce C, Wu A, Cramer D, Terry K. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium. International Journal Of Cancer 2017, 142: 460-469. PMID: 28833087, PMCID: PMC7580880, DOI: 10.1002/ijc.31010.Peer-Reviewed Original ResearchConceptsSevere menstrual painMenstrual painOvarian cancerOdds ratioHistologic subtypePotential confoundersIncreased ovarian cancer riskLogistic regressionSpecific histologic subtypesCommon gynecological conditionEpithelial ovarian cancerMultivariate logistic regressionOvarian cancer riskCase-control studyOvarian Cancer Association ConsortiumInternational pooled analysisUse of hormonesSevere painGynecological conditionsProspective studyPooled analysisClear cellsUndiagnosed endometriosisCancer riskMultinomial logistic regressionHistory of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Minlikeeva AN, Consortium JL, Freudenheim KH, Eng RA, Cannioto G, Friel JB, Szender B, Segal K, Odunsi P, Mayor B, Diergaarde E, Zsiros LE, Kelemen M, Köbel H, Steed A, deFazio SJ, Group PA, Jordan MW, Fasching HA, Beckmann MA, Risch JA, Rossing J, Doherty MT, Chang-Claude T, Goodman R, Dörk F, Edwards RB, Modugno K, Ness M, Matsuo BY, Mizuno EL, Karlan SK, Goode E, Kjær JM, Høgdall KL, Schildkraut DW, Terry EV, Cramer LE, Bandera LA, Paddock LFAG, Kiemeney R, Massuger H, Sutphen A, Anton-Culver U, Ziogas SA, Menon SJ, Gayther A, Ramus CL, Gentry-Maharaj AH, Pearce J, Wu A, Kupryjanczyk PM, Jensen KB, Webb P, Moysich K. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 1470-1473. PMID: 28864456, PMCID: PMC5649363, DOI: 10.1158/1055-9965.epi-17-0367.Peer-Reviewed Original ResearchConceptsProgression-free survivalHistory of endometriosisStage of diseaseOvarian cancer patientsOvarian cancer outcomeCancer outcomesCancer patientsCox proportional hazards regression modelProportional hazards regression modelsHazards regression modelsInvasive ovarian carcinomasOvarian cancer prognosisOvarian Cancer Association ConsortiumPooled HRsConcurrent comorbiditiesHistologic subtypeOvarian carcinomaChronic diseasesOvarian cancerWeight statusNeurologic diseaseCancer prognosisComorbiditiesTreatment efficacyNeurological diseasesBreastfeeding and Endometrial Cancer Risk
Jordan SJ, Na R, Johnatty SE, Wise LA, Adami HO, Brinton LA, Chen C, Cook LS, Dal Maso L, De Vivo I, Freudenheim JL, Friedenreich CM, La Vecchia C, McCann SE, Moysich KB, Lu L, Olson SH, Palmer JR, Petruzella S, Pike MC, Rebbeck TR, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Sponholtz TR, Shu XO, Spurdle AB, Weiderpass E, Wentzensen N, Yang HP, Yu H, Webb PM. Breastfeeding and Endometrial Cancer Risk. Obstetrics And Gynecology 2017, 129: 1059-1067. PMID: 28486362, PMCID: PMC5473170, DOI: 10.1097/aog.0000000000002057.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskEndometrial cancerCancer riskOdds ratioStudy-specific odds ratiosEndometrial Cancer ConsortiumBody mass indexMultivariable logistic regressionConfidence intervalsCase-control studyMaternal benefitsNulliparous womenHistologic subtypeMass indexCommon cancerLower riskStudy heterogeneityCancer ConsortiumControl groupCancerLogistic regressionAverage durationLonger average durationWomenBreastfeedingEpidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer
Kim SJ, Rosen B, Fan I, Ivanova A, McLaughlin JR, Risch H, Narod SA, Kotsopoulos J. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. British Journal Of Cancer 2017, 116: 964-971. PMID: 28208158, PMCID: PMC5379147, DOI: 10.1038/bjc.2017.35.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedCanadaCystadenocarcinoma, SerousEndometrial NeoplasmsEpidemiologic FactorsFemaleFollow-Up StudiesHormone Replacement TherapyHumansMiddle AgedNeoplasm InvasivenessNeoplasm StagingOvarian NeoplasmsParityPregnancyPrognosisReproductive HistoryYoung AdultConceptsOvarian cancer-specific mortalityCancer-specific mortalityHormone replacement therapyRisk of deathEpithelial ovarian cancerOvarian cancerHazard ratioEpidemiologic factorsOvulatory cyclesOvarian cancer-specific deathOvarian cancer-specific survivalInvasive epithelial ovarian cancerBMI 5 yearsCancer-specific survivalCancer-specific deathOntario Cancer RegistryProportional hazards regressionConfidence intervalsBorderline significant associationOvarian cancer developmentLong-term survivalGreater cumulative numberHRT useCancer RegistryHistologic subtype
2016
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer
Hampras SS, Sucheston-Campbell LE, Cannioto R, Chang-Claude J, Modugno F, Dörk T, Hillemanns P, Preus L, Knutson KL, Wallace PK, Hong CC, Friel G, Davis W, Nesline M, Pearce CL, Kelemen LE, Goodman MT, Bandera EV, Terry KL, Schoof N, Eng KH, Clay A, Singh PK, Joseph JM, Aben KK, Anton-Culver H, Antonenkova N, Baker H, Bean Y, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Butzow R, Campbell IG, Carty K, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Dennis J, Despierre E, Dicks E, Doherty JA, du Bois A, Dürst M, Easton D, Eccles D, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Gronwald J, Harrington P, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hogdall C, Hogdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Karlan BY, Kellar M, Kelley JL, Kiemeney LA, Klapdor R, Kolomeyevskaya N, Krakstad C, Kjaer SK, Kruszka B, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lissowska J, Liu S, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Moes-Sosnowska J, Narod SA, Nedergaard L, Nevalinna H, Nickels S, Nevanlinna H, Olson S, Orlow I, Weber R, Paul J, Pejovic T, Pelttari L, Perkins B, Permuth-Wey J, Pike M, Plisiecka-Halasa J, Poole E, Risch H, Rossing M, Rothstein J, Rudolph A, Runnebaum I, Rzepecka I, Salvesen H, Schernhammer E, Schmitt K, Schwaab I, Shu X, Shvetsov Y, Siddiqui N, Sieh W, Song H, Southey M, Tangen I, Teo S, Thompson P, Timorek A, Tsai Y, Tworoger S, Tyrer J, van Altena A, Vergote I, Vierkant R, Walsh C, Wang-Gohrke S, Wentzensen N, Whittemore A, Wicklund K, Wilkens L, Wu A, Wu X, Woo Y, Yang H, Zheng W, Ziogas A, Gayther S, Ramus S, Sellers T, Schildkraut J, Phelan C, Berchuck A, Chenevix-Trench G, Cunningham J, Pharoah P, Ness R, Odunsi K, Goode E, Moysich K. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget 2016, 7: 69097-69110. PMID: 27533245, PMCID: PMC5340115, DOI: 10.18632/oncotarget.10215.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedCarcinoma, Ovarian EpithelialFemaleGene Expression Regulation, NeoplasticGene FrequencyGenetic Predisposition to DiseaseGenotypeHumansMiddle AgedNeoplasms, Glandular and EpithelialOvarian NeoplasmsPolymorphism, Single NucleotideProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaRisk FactorsT-Lymphocytes, RegulatoryConceptsOvarian cancerEpithelial ovarian cancer casesClear cell ovarian cancerClear cell EOCMediators of immunosuppressionSignificant global associationSubset of CD4Regulatory T cellsCell pathwaysOvarian cancer patientsOvarian cancer casesImmune complex receptorsGene-level associationsHistologic subtypeEOC patientsSignificant single SNP associationCancer patientsCancer casesT cellsT lymphocytesClear cellsImmune moleculesMRNA expressionCancerExpression levels
2015
Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium
Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, Fereday S, Hung J, Johnatty SE, Fasching P, Beckmann M, Lambrechts D, Vergote I, Van Nieuwenhuysen E, Lambrechts S, Risch H, Rossing M, Doherty J, Wicklund K, Chang-Claude J, Goodman M, Ness R, Moysich K, Heitz F, du Bois A, Harter P, Schwaab I, Matsuo K, Hosono S, Goode E, Vierkant R, Larson M, Fridley B, Høgdall C, Schildkraut J, Weber R, Cramer D, Terry K, Bandera E, Paddock L, Rodriguez-Rodriguez L, Wentzensen N, Yang H, Brinton L, Lissowska J, Høgdall E, Lundvall L, Whittemore A, McGuire V, Sieh W, Rothstein J, Sutphen R, Anton-Culver H, Ziogas A, Pearce C, Wu A, Webb P. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British Journal Of Cancer 2015, 113: 817-826. PMID: 26151456, PMCID: PMC4559823, DOI: 10.1038/bjc.2015.245.Peer-Reviewed Original ResearchConceptsProgression-free survivalBody mass indexOvarian cancer-specific survivalCancer-specific survivalOvarian cancerHazard ratioHistologic subtypeOverall survivalHigh-grade serous cancerHigher Body Mass IndexInvasive ovarian cancerPooled hazard ratioDifferent histologic subtypesOvarian Cancer Association ConsortiumMajority of womenRandom-effects modelAdverse survivalPooled HRsSerous cancerEndometrioid subtypeMass indexOvarian carcinomaObservational studyModest associationCancer
2014
Risk Factors for Ovarian Cancers With and Without Microsatellite Instability
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J. Risk Factors for Ovarian Cancers With and Without Microsatellite Instability. International Journal Of Gynecological Cancer 2014, 24: 664-669. PMID: 24755492, DOI: 10.1097/igc.0000000000000134.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCanadaCystadenocarcinoma, SerousDNA, NeoplasmEndometrial NeoplasmsFemaleGenetic Predisposition to DiseaseHumansMicrosatellite InstabilityMicrosatellite RepeatsMiddle AgedMutationNeoplasm StagingOvarian NeoplasmsPrognosisRisk FactorsSyndromeUnited StatesConceptsOvarian cancer patientsOral contraceptive useBody mass indexEpithelial ovarian cancerOvarian cancerCancer patientsHistologic subtypeMass indexTubal ligationRisk factorsBRCA2 mutationsContraceptive usePast oral contraceptive usePrimary epithelial ovarian cancerOvarian cancer risk factorsBRCA1 mutationsNational Cancer Institute criteriaProtective factorsSpecific histologic subtypesCancer risk factorsPopulation-based studyMSI-high cancersCases of cancerMSI-high tumorsBRCA2 mutation status
2013
Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls
Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ, Carney ME, Weber RP, Akushevich L, Lo-Ciganic WH, Cushing-Haugen K, Sieh W, Moysich K, Doherty JA, Nagle CM, Berchuck A, Pearce CL, Pike M, Ness RB, Webb PM, Study A, Rossing M, Schildkraut J, Risch H, Goodman M. Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls. Cancer Prevention Research 2013, 6: 811-821. PMID: 23761272, PMCID: PMC3766843, DOI: 10.1158/1940-6207.capr-13-0037.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancerPowder usePopulation-based case-control studyMost histologic subtypesEpithelial ovarian cancer riskBorderline serous tumorsOvarian cancer riskCase-control studySubtype-specific riskConditional logistic regressionHistologic subtypeHistologic typeSerous tumorsPotential confoundersPooled analysisPooled ORsModifiable exposuresCancer riskTumor behaviorEpidemiologic investigationsCancerLogistic regressionLifetime numberCarcinogenic effectsRisk Factors for Ovarian Cancers With and Without Microsatellite Instability
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J. Risk Factors for Ovarian Cancers With and Without Microsatellite Instability. International Journal Of Gynecological Cancer 2013, 23: 1010. PMID: 23748177, PMCID: PMC3740723, DOI: 10.1097/igc.0b013e31829a5527.Peer-Reviewed Original ResearchConceptsOvarian cancer patientsOral contraceptive useBody mass indexEpithelial ovarian cancerOvarian cancerCancer patientsHistologic subtypeMass indexHistologic findingsTubal ligationRisk factorsContraceptive usePast oral contraceptive usePrimary epithelial ovarian cancerOvarian cancer risk factorsBRCA1 mutationsNational Cancer Institute criteriaProtective factorsDifferent histologic findingsSpecific histologic subtypesCancer risk factorsPopulation-based studyMSI-high cancersMSI-high tumorsBRCA2 mutation statusCombined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer
Pearce CL, Rossing MA, Lee AW, Ness RB, Webb PM, Study F, Group A, Chenevix-Trench G, Jordan SM, Stram DA, Chang-Claude J, Hein R, Nickels S, Lurie G, Thompson PJ, Carney ME, Goodman MT, Moysich K, Hogdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Vierkant RA, Weber RP, Ziogas A, Anton-Culver H, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Brinton L, Wentzensen N, Lissowska J, Garcia-Closas M, Massuger LF, Kiemeney LA, Van Altena AM, Aben KK, Berchuck A, Doherty JA, Iversen E, McGuire V, Moorman PG, Pharoah P, Pike MC, Risch H, Sieh W, Stram DO, Terry KL, Whittemore A, Wu AH, Schildkraut JM, Kjaer SK, Consortium F. Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention 2013, 22: 880-890. PMID: 23462924, PMCID: PMC3963289, DOI: 10.1158/1055-9965.epi-12-1030-t.Peer-Reviewed Original ResearchConceptsEnvironmental risk factorsGenetic risk scoreOvarian cancer riskRisk factorsHistologic subtypeRisk scoreOvarian cancerCancer riskHigh genetic risk scoreOvarian cancer case-control studiesCancer case-control studyCase-control studySuch risk factorsGenetic risk factorsRecent genome-wide association studiesTubal ligationRisk differenceDisease riskSubtypesMultivariate modelCancerRisk prediction modelingRiskScoresEffects model
2012
Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium
Setiawan VW, Pike MC, Karageorgi S, Deming SL, Anderson K, Bernstein L, Brinton LA, Cai H, Cerhan JR, Cozen W, Chen C, Doherty J, Freudenheim JL, Goodman MT, Hankinson SE, Lacey JV, Liang X, Lissowska J, Lu L, Lurie G, Mack T, Matsuno RK, McCann S, Moysich KB, Olson SH, Rastogi R, Rebbeck TR, Risch H, Robien K, Schairer C, Shu XO, Spurdle AB, Strom BL, Thompson PJ, Ursin G, Webb PM, Weiss NS, Wentzensen N, Xiang YB, Yang HP, Yu H, Horn-Ross PL, De Vivo I, Group T. Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium. American Journal Of Epidemiology 2012, 176: 269-278. PMID: 22831825, PMCID: PMC3491967, DOI: 10.1093/aje/kws129.Peer-Reviewed Original ResearchConceptsEndometrial Cancer ConsortiumEndometrial cancerLast birthCancer ConsortiumLarge pooled analysisTumor histologic subtypeEndometrial cancer riskExogenous hormone useBody mass indexPooled odds ratioCase-control studyYears of ageHormone useHistologic subtypeMass indexPooled analysisRisk factorsEffect modificationOdds ratioDiagnosis groupsProtective associationCancer riskLower riskNumber of birthsOlder ageHeight, weight, BMI and ovarian cancer survival
Kotsopoulos J, Moody JR, Fan I, Rosen B, Risch HA, McLaughlin JR, Sun P, Narod SA. Height, weight, BMI and ovarian cancer survival. Gynecologic Oncology 2012, 127: 83-87. PMID: 22713293, DOI: 10.1016/j.ygyno.2012.05.038.Peer-Reviewed Original ResearchConceptsBody mass indexOvarian cancer survivalOvarian cancer-specific mortalityCancer-specific mortalityHazard ratioCancer survivalOvarian cancerLarge population-based studyBMI 5 yearsFatal gynecologic malignancyPopulation-based studyEpithelial ovarian cancerConfidence intervalsOvarian cancer prognosisProportional hazards modelChart reviewGynecologic malignanciesClinicopathologic featuresHistologic subtypeMass indexVital statusModifiable factorsRisk factorsHazards modelCancer prognosis
2002
Infertility, Fertility Drugs, and Ovarian Cancer: A Pooled Analysis of Case-Control Studies
Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH. Infertility, Fertility Drugs, and Ovarian Cancer: A Pooled Analysis of Case-Control Studies. American Journal Of Epidemiology 2002, 155: 217-224. PMID: 11821246, DOI: 10.1093/aje/155.3.217.Peer-Reviewed Original ResearchConceptsFertility drug useCase-control studyOvarian cancerDrug useNulligravid womenFertility drugsBorderline serous tumorsOral contraception useMonths of useSubfertile womenHistologic subtypeSerous tumorsPooled analysisTubal ligationOdds ratioUnknown causeBiologic causesFamily historyCancer riskContraception useInfertilityCancerOverall riskConfidence intervalsWomen